| a |
| a |
| a |
| a |
24.77
Publications (17) View all
-
Article: Spatial distribution and survival of human and goat mesenchymal stromal cells on hydroxyapatite and β-tricalcium phosphate.
Henk-Jan Prins, Hugo Fernandes, Henk Rozemuller, Clemens van Blitterswijk, Jan de Boer, Anton C M Martens[show abstract] [hide abstract]
ABSTRACT: The combination of scaffolds and mesenchymal stromal cells (MSCs) is a promising approach in bone tissue engineering (BTE). Knowledge on the survival, outgrowth and bone-forming capacity of MSCs in vivo is limited. Bioluminescence imaging (BLI), histomorphometry and immunohistochemistry were combined to study the fate of gene-marked goat and human MSCs (gMSCs, hMSCs) on scaffolds with different osteoinductive properties. Luciferase-GFP-labelled MSCs were seeded on hydroxyapatite (HA) or β-tricalcium phosphate (TCP), cultured for 7 days in vitro in osteogenic medium, implanted subcutaneously in immunodeficient mice and monitored with BLI for 6 weeks. The constructs were retrieved and processed for histomorphometry and detection of luciferase-positive cells (LPCs). For gMSCs, BLI revealed doubling of signal after 1 week, declining to 60% of input after 3 weeks and remaining constant until week 6. hMSCs showed a constant decrease of BLI signal to 25% of input, indicating no further expansion. Bone formation of gMSCs was two-fold higher on TCP than HA. hMSCs and gMSCs control samples produced equal amounts of bone on TCP. Upon transduction, there was a four-fold reduction in bone formation compared with untransduced hMSCs, and no bone was formed on HA. LPCs were detected at day 14, but were much less frequent at day 42. Striking differences were observed in spatial distribution. MSCs in TCP were found to be aligned and interconnected on the surface but were scattered in an unstructured fashion in HA. In conclusion, the spatial distribution of MSCs on the scaffold is critical for cell-scaffold-based BTE. Copyright © 2012 John Wiley & Sons, Ltd.Journal of Tissue Engineering and Regenerative Medicine 12/2012; · 3.28 Impact Factor -
SourceAvailable from: H-J. Prins
Article: Spatial distribution and survival of human and goat mesenchymal stromal cells on hydroxyapatite and β-tricalcium phosphate
Henk-Jan Prins, Hugo Fernandes, Henk Rozemuller, Clemens van Blitterswijk, Jan de Boer, Anton MartensJournal of Tissue Engineering and Regenerative Medicine 11/2012; · 3.28 Impact Factor -
Article: The influence of genetic factors on the osteoinductive potential of calcium phosphate ceramics in mice.
Ana M C Barradas, Huipin Yuan, Johan van der Stok, Bach Le Quang, Hugo Fernandes, Anindita Chaterjea, Marieke C H Hogenes, Kathy Shultz, Leah Rae Donahue, Clemens van Blitterswijk, Jan de Boer[show abstract] [hide abstract]
ABSTRACT: The efficacy of calcium phosphate (CaP) ceramics in healing large bone defects is, in general, not as high as that of autologous bone grafting. Recently, we reported that CaP ceramics with osteoinductive properties were as efficient in healing an ilium defect of a sheep as autologous bone graft was, which makes this subclass of CaP ceramics a powerful alternative for bone regeneration. Although osteoinduction by CaP ceramics has been shown in several large animal models it is sporadically reported in mice. Because the lack of a robust mouse model has delayed understanding of the mechanism, we screened mice from 11 different inbred mouse strains for their responsiveness to subcutaneous implantation of osteoinductive tricalcium phosphate (TCP). In only two strains (FVB and 129S2) the ceramic induced bone formation, and in particularly, in FVB mice, bone was found in all the tested mice. We also demonstrated that other CaP ceramics induced bone formation at the same magnitude as that observed in other animal models. Furthermore, VEGF did not significantly increase TCP induced bone formation. The mouse model here described can accelerate research of osteoinductive mechanisms triggered by CaP ceramics and potentially the development of therapies for bone regeneration.Biomaterials 05/2012; 33(23):5696-705. · 7.40 Impact Factor -
Article: Endothelial differentiation of mesenchymal stromal cells.
Karolina Janeczek Portalska, Anne Leferink, Nathalie Groen, Hugo Fernandes, Lorenzo Moroni, Clemens van Blitterswijk, Jan de Boer[show abstract] [hide abstract]
ABSTRACT: Human mesenchymal stromal cells (hMSCs) are increasingly used in regenerative medicine for restoring worn-out or damaged tissue. Newly engineered tissues need to be properly vascularized and current candidates for in vitro tissue pre-vascularization are endothelial cells and endothelial progenitor cells. However, their use in therapy is hampered by their limited expansion capacity and lack of autologous sources. Our approach to engineering large grafts is to use hMSCs both as a source of cells for regeneration of targeted tissue and at the same time as the source of endothelial cells. Here we investigate how different stimuli influence endothelial differentiation of hMSCs. Although growth supplements together with shear force were not sufficient to differentiate hMSCs with respect to expression of endothelial markers such as CD31 and KDR, these conditions did prime the cells to differentiate into cells with an endothelial gene expression profile and morphology when seeded on Matrigel. In addition, we show that endothelial-like hMSCs are able to create a capillary network in 3D culture both in vitro and in vivo conditions. The expansion phase in the presence of growth supplements was crucial for the stability of the capillaries formed in vitro. To conclude, we established a robust protocol for endothelial differentiation of hMSCs, including an immortalized MSC line (iMSCs) which allows for reproducible in vitro analysis in further studies.PLoS ONE 01/2012; 7(10):e46842. · 4.09 Impact Factor -
Article: 'Smart' biomaterials and osteoinductivity.
Huipin Yuan, Hugo Fernandes, Pamela Habibovic, Jan de Boer, Ana M C Barradas, William R Walsh, Clemens A van Blitterswijk, Joost D De BruijnNature Reviews Rheumatology 04/2011; 7(4):c1; author reply c2. · 8.39 Impact Factor